Story
Mirum Pharma Rises as Investors Await Key FDA Decision on FOP Drug
Summary
Shares of Mirum Pharmaceuticals (MIRM) climbed as the company nears a critical FDA approval decision for its rare disease drug, zilurgisertib. The regulator is expected to announce its verdict by the September 26 PDUFA date.
Mirum Pharmaceuticals (Nasdaq: MIRM) saw its shares rise in afternoon trading as investors positioned themselves ahead of a key regulatory decision from the U.S. Food and Drug Administration (FDA) on its investigational drug, zilurgisertib. The stock climbed 1.0% to $90.23 ahead of the agency's verdict, expected by the scheduled Prescription Drug User Fee Act (PDUFA) date of September 26, 2026.
FDA Decision Looms
The FDA is set to rule on the New Drug Application (NDA) for zilurgisertib, an oral ALK2 inhibitor being developed for the treatment of fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare and severely disabling genetic disorder that causes abnormal bone growth in soft tissues, leading to progressive immobility.
The agency granted the application a Priority Review, a designation reserved for drugs that, if approved, would offer significant improvements in the safety or effectiveness of treating serious conditions. The upcoming PDUFA date marks the deadline for the FDA's decision, making the preceding trading session a natural point for investors to adjust their holdings.
Market and Corporate Context
AdInvestor positioning ahead of the binary regulatory event was the primary driver for the stock's move. The share price remains well below its 52-week high of $130, suggesting potential upside for the stock should the FDA's decision be favorable. A positive broader market, with the S&P 500, Dow Jones, and Nasdaq all posting gains, also provided a supportive backdrop for the trading session.
Mirum's application is supported by data from its pivotal Phase 2 PROGRESS study. The company licensed the global development rights for zilurgisertib from Incyte. Beyond this single catalyst, Mirum has recently strengthened its fundamentals by:
- Raising its full-year 2026 net product sales guidance to a range of $680 million to $700 million.
- Appointing Rob Myers, M.D., a hepatologist with over two decades of experience, as its new Chief Medical Officer.
- Maintaining 'Buy' and 'Outperform' ratings from multiple Wall Street analysts.
Read next
More on Stocks
European Telecoms Face AI-Driven Price Pressure, Bank of America Warns
Bank of America analysts report that while AI agents could increase customer churn for European telecom operators by simplifying price comparisons, the technology also offers powerful tools for sales and personalized customer retention.
ShinyHunters Hackers Renew Attacks on Oracle PeopleSoft Flaw, Google's Mandiant Reports
Google's cybersecurity unit, Mandiant, reports that the hacking group ShinyHunters has resumed and adapted its exploitation of a known vulnerability in Oracle's PeopleSoft enterprise software, targeting organizations that failed to apply a full security patch.
Manulife Stock Climbs, Supported by Cross-Border Investor Optimism
Shares of Manulife Financial gained on Tuesday, buoyed by a strong performance in U.S. markets rather than any specific company news. The stock's move is also supported by a bullish technical posture and positive analyst ratings.
Escondida Union Rejects BHP's Bid to Pause Talks After Fatal Accident
A union at the world's largest copper mine, Escondida, has rejected a request from operator BHP to postpone contract negotiations following a fatal accident earlier this week. The union accused the company of using the tragedy to delay the collective bargaining process.